Abstract
HER2/neu-derived peptides inducing MHC class II-restricted CD4+ T helper lymphocyte (Th) responses, although critical for tumour rejection, are not thoroughly characterized. Here, we report the generation and characterization of CD4+ T cell clones specifically recognizing a HER-2/neu-derived peptide (776–788) [designated HER2(776–788)]. Such clones yielded specific proliferative and cytokine [gamma-interferon(IFN)-γ] responses when challenged with autologous dendritic cells (DCs) loaded with HER2(776–788). By performing blocking studies with monoclonal antibodies (MAbs) and by using DCs from allogeneic donors sharing certain HLA-DR alleles, we found that HER2(776–788) is a promiscuous peptide presented, at least, by DRB5*0101, DRB1*0701 and DRB1*0405 alleles. One TCRVbeta6.7+ clone recognized the HLA-DRB5*0101+ FM3 melanoma cell line transfected with a full length HER-2/neu cDNA. Moreover, this clone recognized the HER-2/neu+ SKBR3 breast cancer cell line induced to express HLA-DR, thus demonstrating that HER2(776–788) represents a naturally processed and presented epitope. Our data demonstrate that helper peptide HER2(776–788) represents a promiscuous epitope binding to at least three HLA-DR alleles, thus offering a broad population coverage. The use of antigenic peptides presented by major histocompatibility complex (MHC) class II in addition to those presented by class I may improve the therapeutic efficacy of active immunization. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Anderson BW, Kudelka AP, Honda T, Pollack MS, Gershenson DM, Gillogly MA, Murray JL and Ioannides CG (2000) Induction of determinant spreading and of Th1 responses by in vitro stimulation with HER-2 peptides. Cancer Immunol Immunother 49: 459–468
Baxevanis CN, Spanakos G, Voutsas IF, Gritzapis AD, Tsitsilonis OE, Mamalaki A and Papamichail M (1999) Increased generation of autologous tumor-reactive lymphocytes by anti-CD3 monoclonal antibody and prothymosin α. Cancer Immunol Immunother 48: 71–84
Baxevanis CN, Voutsas IF, Tsitsilonis OE, Gritzapis AD, Sotiriadou R and Papamichail M (2000) Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor. J Immunol 164: 3902–3912
Busch R, Hill CM, Hayball JD, Lamb JR and Rothbard JB (1991) Effect of natural polymorphism at residue 86 of the HLA-DR beta chain on peptide binding. J Immunol 147: 1292–1298
Cheever MA, Disis ML, Bernhard H, Gralow JR, Hand SL, Huseby ES, Qin HL, Takahashi M and Chen W (1995) Immunity to oncogenic proteins. Immunol Rev 145: 33–59
Coppin HL, Carmichael P, Lombardi G, L’Faqihi FE, Salter R, Parham P, Lechler RI and DE Preval C (1993) Position 71 in the alpha helix of the DRbeta domain is predicted to influence peptide binding and plays a central role in allorecognition. Eur J Immunol 23: 343–349
Demotz S, Barbey C, Corradin G, Amoroso A and Lanzavecchia A (1993) The set of naturally processed peptides displayed by DR molecules is tuned by polymorphism of residue 86. Eur J Immunol 23: 425–432
Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B, Jeschke M, Lydon N, McGlynn E, Livingston RB, Moe R and Cheever MA (1994) Existent T-cells and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 54: 16–20
Disis ML and Cheever MA (1997) HER-2/neu protein: A target for antigen-specific immunotherapy of human cancer. Adv Cancer Res 71: 342–371
Doherty DG, Penzotti JE, Koelle DM, Kwok WW, Lybrand TP, Masewicz S and Nepom GT (1998) Structural basis of specificity and degeneracy of T cell recognition: pluriallelic restriction of T cell responses to a peptide antigen involves both specific and promiscuous interactions between the T cell receptor, peptide, and HLA-DR. J Immunol 161: 3527–3535
Fisk B, Blevins TL, Wharton JT and Ioannides CG (1995) Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 181: 2109–2117
Fisk B, Hudson JM, Kavanagh J, Wharton JT, Murray JL, Ioannides CG and Kudelka AP (1997) Existent proliferative response of peripheral blood mononuclear cells from healthy donors and ovarian cancer patients to HER-2 peptides. Anticancer Res 17: 45–53
Graham FL and Van der Eb AJ (1973) A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 52: 456–467
Halder T, Pawelec G, Kirkin AF, Zeuthen J, Meyer HE, Kun L and Kalbacher H (1997) Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3. Cancer Res 57: 3238–3244
Hemmer B, Pinilla C, Gran B, Vergelli M, Ling N, Conlon P, McFarland HF, Houghten R and Martin R (2000) Contribution of individual amino acids within MHC molecule or antigenic peptide to TCR ligand potency. J Immunol 164: 861–871
Hung MC and Lau YK (1999) Basic science of HER-2/neu: a review. Semin Oncol 26: 51–59
Ioannides CG, Freedman RS, Platsoukas CD, Rashed S and Kim YP (1991) Cytotoxic T cell clones isolated from ovarian tumor-infiltrating lymphocytes recognize multiple antigenic epitopes on autologous tumor cells. J Immunol 146: 1700–1707
Jaeger E, Jaeger D, Karbach J, Chen YT, Ritter G, Nagata Y, Gnjatik S, Stockert E, Arand M, Old LJ and Knuth A (2000) Identification of NY-ESO-1 epitopes presented by human histocombatibility antigen (HLA)-DRB4*101–103 and recognized by CD4+ T lymphocytes of patients with NY-ESO-1-expressing melanoma. J Exp Med 191: 625–630
Karr RW, Panina-Bordignon P, Yu WY and Lanzavecchia A (1991) Antigen-specific T cells with monogamous or promiscuous restriction patterns are sensitive to different HLA-DR beta chain substitutions. J Immunol 146: 4242–4247
Keene JA and Forman J (1982) Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J Exp Med 155: 768–782
Kobayashi H, Wood M, Song Y, Appella E and Celis E (2000) Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen. Cancer Res 60: 5228–5236
Linehan DC, Goedegebuure PS, Peoples GE, Rogers SO and Eberlein TJ (1995) Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer. J Immunol 155: 4486–4491
Martínez-Soria E, Steimle V, Burkhardt C, Beffy P, Tiercy JM, Epplen JT, Mach B and Irlé C (1994) An HLA-DRB alpha-helix motif shared by DR11 and DR8 alleles is implicated in the pluriallelic restriction of peptide-specific T-cell lines. Hum Immunol 40: 279–290
McKinney JS, Fu XT, Swearingen C, Klohe E and Karr RW (1994) Individual effects of the DR11-variable beta-chain residues 67, 71, and 86 upon DR (alpha, betal*1101)-restricted, peptide-specific-T cell proliferation. J Immunol 153: 5564–5571
Pardoll DM and Topalian SL (1998) The role of CD4+ T cell responses in anti tumor immunity. Curr Opin Immunol 10: 588–594
Peoples GE, Yoshino I, Douville CC, Andrews JV, Goedegebuure PS and Eberlein TJ (1994) TCR Vbeta3+ and V beta6+ CTL recognize tumor-associated antigens related to HER2/neu expression in HLA-A2+ ovarian cancers. J Immunol 152: 4993–4999
Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I and Eberlein TJ (1995) Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad USA 92: 432–436
Reichert A, Heitz D, Echner H, Voelter W and Faulstich H (1996) Identification of contact sites in the actin-thymosin β4 complex by distance-dependent thiol cross-linking. J Biol Chem 271: 1301–1308
Ridge JP, Di Rosa F and Matzinger P (1998) A conditioned dendritic cell can be temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393: 474–478
Rongcun Y, Salazar-Onfray F, Charo J, Malmberg KJ, Evrin K, Maes H, Kono K, Hising C, Petersson M, Larsson O, Lan L, Appella E, Sette A, Celis E and Kiessling R (1999) Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J Immunol 163: 1037–1044
Schoenberger SP, Toes RE, Van Der Voort EI, Offringa R and Melief CJ (1998) T-cell help for cytotoxic T lymphocytes is mediated CD40-CD40L interactions. Nature 393: 480–483
Schultz LB and Weber BL (1999) Recent advances in breast cancer biology. Curr Opin Oncol 11: 429–434
Simpson E and Gordon RD (1997) Responsiveness to H-Y Antigen, Ir-gene complementation and target specificity. Immunol Rev 35: 59–75
Southwood S, Sidney J, Kondo A, Del Guercio MF, Appella E, Hoffman S, Kubo RT, Chesnut RW, Grey HM and Sette A (1998) Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol 160: 3363–3373
Topalian SL, Gonzales MI, Parkhurst M, Li YF, Southwood S, Sette A and Rosenberg SA (1996) Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med 183: 1965–1971
Tuttle TM, Anderson BW, Thompson WE, Lee JE, Sahin A, Smith TL, Grabstein KH, Wharton JT, Ioannides CG and Murray JL (1998) Proliferative and cytokine responses to class II HER-2/neu-associated peptides in breast cancer patients. Clin Cancer Res 4: 2015–2024
Wang RF and Rosenberg SA (1999) Human tumor antigens for cancer vaccine development. Immunol Rev 170: 85–100
Yoshino I, Goedegebuure PS, Peoples GE, Parikh AS, Dimaio JM, Lyerly HK, Gazdar AF and Eberlein TJ (1994) HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res 54: 3387–3390
Zeliszewski D, Golvano JJ, Gaudebout P, Dorval I, Freidel C, Gebuhrer L, Betuel H, Borras-Cuesta F and Sterkers G (1993) Implication of HLA-DR residues at positions 67, 71, and 86 in interaction between HLA-DR11 and peptide HA306-320. J Immunol 151: 6237–6247
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Sotiriadou, R., Perez, S., Gritzapis, A. et al. Peptide HER2(776–788) represents a naturally processed broad MHC class II-restricted T cell epitope. Br J Cancer 85, 1527–1534 (2001). https://doi.org/10.1054/bjoc.2001.2089
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.2089
Keywords
This article is cited by
-
Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide
Journal for ImmunoTherapy of Cancer (2016)
-
A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that HLA-A*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefit
Cancer Immunology, Immunotherapy (2015)
-
AE37 peptide vaccination in prostate cancer: a 4-year immunological assessment updates on a phase I trial
Cancer Immunology, Immunotherapy (2013)
-
Modulation of tumor immunity by therapeutic monoclonal antibodies
Cancer and Metastasis Reviews (2011)
-
Ii-Key/HER-2/neu(776-90) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors
Cancer Immunology, Immunotherapy (2007)